FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2739955649> ?p ?o ?g. }

• W2739955649 abstract "Background: PI3K/Akt/mTORC1 signaling pathway is aberrantly activated in renal cell carcinoma (RCC). We previously demonstrated that glycogen synthase kinase-3β (GSK-3β) positively regulated RCC proliferation. Herein, we aimed to investigate how the mTORC1 downstream substrate 4EBP1 is directly regulated by GSK-3β leading to acquisition of clinical chemoresistance to mTORC1 inhibitor (mTORi). Methods: The expression and phosphorylation of molecules in the subcellular pathways were examined by immunoblotting in surgically resected RCC tissues and human RCC cell lines including ACHN. Rapamycin-resistant ACHN cells (ACHN/RR) were generated by chronic exposure to an mTORi, rapamycin. Cell viability was investigated by MTS assay. The direct role of GSK-3β in regulating 4EBP1 was evaluated by an in vitro kinase assay. Pharmacological inhibition of GSK-3β, PI3K/Akt/mTORC1 pathway, and mTORC1 was achieved by treatment with AR-A014418, LY294002, and rapamycin, respectively. The effects of drug combination were determined using CompuSyn software. GSK-3β expression was evaluated in pathological RCC tissues obtained by nephrectomy from patients with metastatic RCC (mRCC), nine of whom were treated with mTORi as systemic therapies. GSK-3β expression was immunohistochemically graded as high and low expression using a semi-quantitative method based on positive staining intensity. Survival intervals were evaluated using the Kaplan-Meier method and log-rank test. Significance level was set as 0.05 in statistical analysis using a freeware R. Results: Inhibition of PI3K/Akt/mTORC1 pathway and mTORi treatment sufficiently decreased pS6RP, but only moderately decreased p4EBP1. In contrast to the effect of rapamycin, AR- A014418 remarkably inhibited cell proliferation, and rapidly suppressed p4EBP1 in ACHN and ACHN/RR. In vitro kinase assays showed that recombinant GSK-3β phosphorylated recombinant 4EBP1 at Thr37, Thr46, Thr70 and Ser65, and these phosphorylations were blocked by GSK-3 inhibitor. A combination of AR- A014418 and rapamycin produced an additive effect at lower concentrations, and were antagonistic at higher concentrations. Immunoblotting demonstrated that 4EBP1 and p4EBP1 expression in RCC tissues was positively correlated with GSK-3β expression. Overall survival was significantly short in patients with high GSK-3β expression, compared with those having low expression (n = 25 and 14, respectively, p = 0.04). In addition, high GSK-3β expression in tumors tended to shorten progression-free intervals in mRCC patients treated with mTORi. Conclusions: High GSK-3ββ expression and direct GSK-3β/4EBP1 pathway can be a key mechanism for RCC acquiring clinical chemoresistance to mTORCi. Activation of the direct pathway might be predictive of poor prognosis of mRCC patients. Citation Format: Hiromi Ito, Sei Naito, Osamu Ichiyanagi, Hidenori Kanno, Yuta Kurota, Atushi Yamagishi, Vladimir Bilim, Yoshihiko Tomita, Tomoyuki Kato, Akira Nagaoka, Norihiko Tsuchiya. Acquisition of chemoresistance to mTORC1 inhibition due to activation of the GSK-3 β/4EBP1 pathway might predict poor prognosis of mRCC patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4120. doi:10.1158/1538-7445.AM2017-4120" @default.
• W2739955649 created "2017-08-08" @default.
• W2739955649 creator A5007596741 @default.
• W2739955649 creator A5010300952 @default.
• W2739955649 creator A5011987568 @default.
• W2739955649 creator A5015451902 @default.
• W2739955649 creator A5023764914 @default.
• W2739955649 creator A5024597836 @default.
• W2739955649 creator A5027892519 @default.
• W2739955649 creator A5029120542 @default.
• W2739955649 creator A5052645092 @default.
• W2739955649 creator A5055477590 @default.
• W2739955649 creator A5074696076 @default.
• W2739955649 date "2017-07-01" @default.
• W2739955649 modified "2023-09-25" @default.
• W2739955649 title "Abstract 4120: Acquisition of chemoresistance to mTORC1 inhibition due to activation of the GSK-3 β/4EBP1 pathway might predict poor prognosis of mRCC patients" @default.
• W2739955649 doi "https://doi.org/10.1158/1538-7445.am2017-4120" @default.
• W2739955649 hasPublicationYear "2017" @default.
• W2739955649 type Work @default.
• W2739955649 sameAs 2739955649 @default.
• W2739955649 citedByCount "0" @default.
• W2739955649 crossrefType "proceedings-article" @default.
• W2739955649 hasAuthorship W2739955649A5007596741 @default.
• W2739955649 hasAuthorship W2739955649A5010300952 @default.
• W2739955649 hasAuthorship W2739955649A5011987568 @default.
• W2739955649 hasAuthorship W2739955649A5015451902 @default.
• W2739955649 hasAuthorship W2739955649A5023764914 @default.
• W2739955649 hasAuthorship W2739955649A5024597836 @default.
• W2739955649 hasAuthorship W2739955649A5027892519 @default.
• W2739955649 hasAuthorship W2739955649A5029120542 @default.
• W2739955649 hasAuthorship W2739955649A5052645092 @default.
• W2739955649 hasAuthorship W2739955649A5055477590 @default.
• W2739955649 hasAuthorship W2739955649A5074696076 @default.
• W2739955649 hasConcept C502942594 @default.
• W2739955649 hasConcept C55493867 @default.
• W2739955649 hasConcept C62112901 @default.
• W2739955649 hasConcept C62478195 @default.
• W2739955649 hasConcept C71924100 @default.
• W2739955649 hasConcept C75217442 @default.
• W2739955649 hasConcept C86554907 @default.
• W2739955649 hasConcept C86803240 @default.
• W2739955649 hasConcept C95444343 @default.
• W2739955649 hasConcept C98490376 @default.
• W2739955649 hasConceptScore W2739955649C502942594 @default.
• W2739955649 hasConceptScore W2739955649C55493867 @default.
• W2739955649 hasConceptScore W2739955649C62112901 @default.
• W2739955649 hasConceptScore W2739955649C62478195 @default.
• W2739955649 hasConceptScore W2739955649C71924100 @default.
• W2739955649 hasConceptScore W2739955649C75217442 @default.
• W2739955649 hasConceptScore W2739955649C86554907 @default.
• W2739955649 hasConceptScore W2739955649C86803240 @default.
• W2739955649 hasConceptScore W2739955649C95444343 @default.
• W2739955649 hasConceptScore W2739955649C98490376 @default.
• W2739955649 hasLocation W27399556491 @default.
• W2739955649 hasOpenAccess W2739955649 @default.
• W2739955649 hasPrimaryLocation W27399556491 @default.
• W2739955649 hasRelatedWork W1601647392 @default.
• W2739955649 hasRelatedWork W1974599057 @default.
• W2739955649 hasRelatedWork W2014865890 @default.
• W2739955649 hasRelatedWork W2022014232 @default.
• W2739955649 hasRelatedWork W2025554600 @default.
• W2739955649 hasRelatedWork W2046635534 @default.
• W2739955649 hasRelatedWork W2065610474 @default.
• W2739955649 hasRelatedWork W2071867468 @default.
• W2739955649 hasRelatedWork W2088302799 @default.
• W2739955649 hasRelatedWork W2324191565 @default.
• W2739955649 hasRelatedWork W2329334073 @default.
• W2739955649 hasRelatedWork W2404229689 @default.
• W2739955649 hasRelatedWork W2596119653 @default.
• W2739955649 hasRelatedWork W2739670599 @default.
• W2739955649 hasRelatedWork W2918898389 @default.
• W2739955649 hasRelatedWork W2948535740 @default.
• W2739955649 hasRelatedWork W2955062045 @default.
• W2739955649 hasRelatedWork W2968401736 @default.
• W2739955649 hasRelatedWork W2970508833 @default.
• W2739955649 hasRelatedWork W2992233982 @default.
• W2739955649 isParatext "false" @default.
• W2739955649 isRetracted "false" @default.
• W2739955649 magId "2739955649" @default.
• W2739955649 workType "article" @default.